Estrogens can lead to benign prostatic hypertrophy (BPH) through two different ways: a) acting directly on stroma by specific receptors; b) increasing DHT prostatic receptors. Mepartricin performs an anti-estrogenic action at intestinal level only, increasing fecal excretion and reducing their serum and prostatic level. A European study evaluated 178 patients, 88 treated with Mepartricin and 98 with placebo. The group treated with Mepartricin showed from the first month a better urinary flow and a significant decrease of IPSS score.
|Translated title of the contribution||Benign prostate hypertrophy and Mepartricin|
|Number of pages||3|
|Journal||Rivista Italiana di Biologia e Medicina|
|Publication status||Published - 1997|
ASJC Scopus subject areas